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Bryostatin is a natural product that has many medically promising biological activities. Understanding how
bryostatin is assembled by the producing symbiotic bacterium has been hampered by the limited
availability of genetic information. In the new report, Buchholz et al. (2010) circumvented this issue by using
surrogates to replace missing catalytic components.The study of the biosynthesis of natural
products has benefited enormously from
the technological advances in DNA
sequencing and bioinformatics. It is now
routine to associate a cluster of genes
with the production of a particular natural
product and propose a biosynthetic
scheme based on the bioinformatic
analysis of the encoded proteins. These
hypothetic biosynthesis schemes are
subsequently tested by biochemical and
genetic studies. While routine for many
systems, there are unique challenges
when studying the biosynthesis of natural
products produced by microorganisms
that cannot be cultured from their natural
environment. The challenge comes from
the fact that in many cases the com-
pleteness of the genetic information is
in question because the structure of the
associated natural product calls for
catalytic components that are not en-
coded by the available DNA sequence.
In these circumstances, testing hypoth-
eses for even early biosynthesis steps
may be inhibited by the apparent absence
of key catalytic components. In this issue,
Buchholz et al. (Buchholz et al., 2010)
demonstrate a valuable way to circum-
vent this problem in the analysis of bryos-
tain biosynthesis. Using surrogate acetyl-
acyl carrier protein (ACP) donors in place
of the cognate counterpart that has
yet to be identified, they were able to
biochemically validate the proposed
function of BryR, a 3-hydroxy-3-methyl-
glutaryl-CoA synthase (HMGS) homolog.
Furthermore, replacing missing com-
ponents by surrogates is a step toward
the heterologous production of the bryos-
tatins in a culturable host even without
identifying all the cognate genes/
enzymes.Polyketides are a diverse group of
natural products characterized by the
polymerization of short carboxylic acids
by large enzyme complexes called
polyketide synthases (PKSs). PKSs,
particularly type I PKSs, are capable of
using a diversity of starter units and
extender units. Substituents at the
a-carbons of these precursors is one
mechanism for branching away from the
core of a polyketide, and much work has
gone into understanding how these
precursors are biosynthesized (Chan
et al., 2009; Moore and Hertweck, 2002).
Less common are polyketides that have
branching at the b-carbons. The mecha-
nism for how this type of branching is
biosynthesized remained elusive until
recently when a number of groups began
to decipher its mechanism (Calderone,
2008). The enzymology involved in b-
branching typically involves the following
set of proteins, referred to as the HMGS
cassette: a free-standing donor ACP
(ACPD), a HMGS homolog, a decarboxy-
lating ketosynthase (KSDC) domain, and
one or two enoyl-CoA hydratase (ECH)
homologs (Figure 1). In the canonical
b-branching pathway, an acyltransferase
domain loads a malonyl unit onto ACPD.
The KSDC domain catalyzes the decar-
boxylation of the malonyl unit on ACPD,
generating acetyl-S-ACPD. The HMGS
homolog subsequently catalyzes the aldol
attack by the acetyl-S-ACPD on a b-keto-
thioester intermediate on an acceptor
ACP (ACPA) within the PKS. This gener-
ates an HMG-S-ACPA intermediate that
can be dehydrated and decarboxylated
by the ECH homologs to generate the
b-branched product (Figure 1). While this
is the canonical pathway, diversion from
this pathway extends the b-branchingChemistry & Biology 17, October 29, 2010 ªstructural possibilities, but it is hypothe-
sized that they will all involve an HMGS-
like homolog, with the exception of
rhizoxin biosynthesis (Partida-Martinez
and Hertweck, 2007).
Bryostatin is a polyketide natural
product with a number of promising bio-
logical activities including anticancer,
neuroprotective, and reduction in the
levels of a toxic protein implicated in
Alzheimer’s disease (Banerjee et al.,
2008; Khan et al., 2009). The excitement
for using bryostatin for these medical
purposes is tempered by the fact that it
is produced in small quantities by an
unculturable bacterium that is a symbiont
of a marine bryozoan (Sudek et al., 2007).
Additionally, its total chemical synthesis is
difficult; thus, eliminating the possibility of
using total synthesis as a means for
obtaining more material (Singh et al.,
2008). To circumvent these issues, Sher-
man and Haygood have collaborated to
access the genetic information that codes
for the biosynthesis enzymes with the
ultimate goal of moving these to a heterol-
ogous host for production (Sudek et al.,
2007). To this end, they have identified
candidate gene clusters encoding bryos-
tatin biosynthesis enzymes, but the gene
clusters appear incomplete and the
‘‘missing’’ genetic information has yet to
be identified. This initially appeared to
limit the analysis of the pathway. This
problem was sidestepped by the use of
surrogate catalytic components from
related enzymology.
A modified HMGS cassette is hypothe-
sized to be involved in the generation of
the two b-branching points of bryostatin
(Figure 1). It is not clear, however, how
the b-branching initiates because the
gene clusters encode for HMGS (BryR)2010 Elsevier Ltd All rights reserved 1045
Figure 1. Schematic of the Canonical b-Branching Pathway and the Relationship of This Pathway to Bryostatin Production
The enzyme characterized in this study is an HMGS homolog BryR.
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an ACPD homolog. To investigate whether
BryR functions as an HMGS, Buchholz
et al. searched for surrogate ACPs to
function in place of the cognate ACPD.
They tested a variety of ACPs from type I
and II PKSs, ACPs involved in bacterial
fatty acid biosynthesis, and ACPDs
from other HMGS cassettes. Each of
these ACPs was modified to form acetyl-
S-ACPs, and these were tested for
whether they were competent as sub-
strates for BryR. BryR was shown to
only recognize the acetyl group when
tethered to ACPDs from other HMGS
cassettes. This strongly suggests BryR
specifically recognizes an ACPD-linked
substrate in vivo. Furthermore, the failure
of the authors to detect interactions
between BryR and other ACPs, even
though these ACPs carried the same
substrate as the ACPDs, suggests pro-
tein-protein interactions between BryR
and the ACPD are essential for substrate
recognition. A model acetoacetyl-S-
ACPA, from Module 3 of the bryostatin
PKS, was used to confirm that BryR was1046 Chemistry & Biology 17, October 29, 20able to catalyze the complete HMGS
reaction.
The use of surrogate proteins by
Buchholz et al. enabled them to biochemi-
cally verify the function of BryR and
address how b-branching initiates during
bryostatin biosynthesis. The applications
for this approach are two fold: first, this or
similar methods can be used to test
the catalytic functions of domains in other-
wise ‘‘incomplete’’ biosynthetic pathways;
second, the method carries with it
important implications on metabolic engi-
neering. Marine-derived natural products
showing interesting biological activities
are often produced by unculturable bacte-
rial symbionts of eukaryotic hosts. Thus far
the only way to obtain large quantities of
such compounds has been to purify them
from enormous quantities of the host
organisms. It is of interest to produce
these molecules from a heterologous
host so that appropriate quantities can
be acquired. When dealing with missing
biosynthetic components, using surro-
gates is a promising solution, as well as
a step toward heterologous production.10 ª2010 Elsevier Ltd All rights reservedREFERENCES
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